ImmunoGen Regroups After FORWARD Setback, Looks To New Ovarian Cancer Phase III
Executive Summary
US FDA dashes hopes for accelerated approval of mirvetuximab soravtansine based on subgroup data, but will work with ImmunoGen to design a new trial focused on highly FRα-positive patients.